Extrapulmonary tuberculosis. (December 2017)

• Record Type: Journal Article
• Authors: Peirse, Mary; Houston, Angela
• Is Part Of: Medicine. Volume 45:Number 12(2017)
• Page Start: 747
• Page End: 752
• Publication Date: 2017-12
• Subjects: Extrapulmonary tuberculosis -- granuloma -- HIV -- lymphadenitis -- miliary tuberculosis -- MRCP -- pericarditis -- spondylodiscitis -- tuberculosis -- Xpert MTB/RIF®; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Médecine factuelle -- Périodiques; Medicine; Periodicals; Electronic journals; Electronic journals; 610
• DOI: 10.1016/j.mpmed.2017.09.008
• Languages: English
• ISSNs: 1357-3039

Abstract

Abstract: Extrapulmonary tuberculosis (EPTB) now represents over half of all diagnosed cases of TB in the UK and is increasingly seen in patients with immunosuppression or HIV. It is usually caused by reactivation of latent infection and can cause disease at almost any site, most commonly the lymph nodes (23%), pleura (8.2%), gastrointestinal tract (5.9%), bone (6.7%), central nervous system (4.4%) and genitourinary system (2.1%). Manifestations depend on the site of disease, making diagnosis challenging as EPTB can mimic many other diseases. Hence TB should be considered in the differential diagnosis of any sick patient. A diagnosis of EPTB should trigger a search for concomitant pulmonary disease, which has implications for infectivity, and an HIV test (as with any TB diagnosis). Obtaining appropriate samples for microbiological diagnosis is vital for effective management, especially as drug resistance becomes more common. Treatment is generally with standard quadruple therapy for 6 months (extended in TB meningitis); adjunctive corticosteroid therapy is of proven value in TB pericarditis and meningitis.